Eberhard Karls Universitaet Tuebingen — Clinical Trial Site

15 Registered trials

4 Currently recruiting

Organisation

Eberhard Karls Universitaet Tuebingen

Location

Tuebingen, Germany

Identifier

ORG-100015453

Address

Wilhelmstrasse 27, Innenstadt, 72074, Germany

Departments

#2061:Onkologie,Hämatologie, Immunologie, Rheumatologie und Pulmonologie
#2107 Medizinische Klinik IV, Diabetologie, Endokrinologie, Nephrologie
5207: Medizinische Klinik IV, Diabetologie, Endokrinologie, Nephrologie
Department of Dermatology
Department of Ophthalmology
Dermatology
Hautklinik
Immundermatologie
Institute of Tropical Medicine
Klinik für Hämatologie und Stammzelltransplantation
N/A
Oncology
Universitaetsklinikum Tuebingen / Universitaets-Hautklinik Psoriasiszentrum

Clinical trials at this site (15)

Search interface

A clinical trial to assess the efficacy and safety of ADX-308, a new type of treatment for Geographic Atrophy (GA), an advanced stage of eye… Pending

2025-521779-30-00 Geographic atrophy secondary to age-related macular deg 4
A randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of 250 mg lebrikizumab in patients with localized s… Pending

2025-524435-39-00 Localized Scleroderma 4
A phase I/IIa, dose-finding study to assess the safety and immunogenicity of an Orf virus-based COVID-19 vaccine booster (Prime-2-CoV_Beta) … Recruiting

2024-511266-36-00 The clinical trial itself does not investigate a medica 7 2026-03-26
A Study of the Efficacy and Safety of JNJ-77242113 in Biologic-experienced Participants with Active Psoriatic Arthritis Recruiting

2024-517284-23-00 Active Psoriatic Arthritis 5 2025-04-23
A trial to learn if AZD0305 alone and in combination with other cancer treatments is safe and works in adults with multiple myeloma Recruiting

2023-508590-89-00 Multiple Myeloma 7 2024-06-25
Study of the efficacy of intratumoral injections of L19IL2 + L19TNF followed by surgery to prevent or retard appearance of new metastases Recruiting

2023-507119-36-00 Malignant melanoma of the skin in patients with locally 5 2022-05-09
A Study of the Efficacy and Safety of JNJ-77242113 in Biologic-naïve Participants with Active Psoriatic Arthritis Ended

2023-509239-19-00 Active Psoriatic Arthritis 5 2025-04-03
A Study to Investigate Tolerability and Efficacy of Asciminib (Oral) Versus Nilotinib (Oral) in Adult Participants (≥18 Years of Age) With N… Ended

2024-510947-71-00 Chronic Myeloid Leukemia 5 2022-11-21
A study in patients with skin cancer Ended

2024-516914-39-00 Metastatic or unresectable melanoma 5 2022-04-27
A rollover extension program (REP) to evaluate the long-term safety and tolerability of open label iptacopan in adult participants with prim… Ended

2023-508690-92-00 IgA Nephropathy 11 2021-09-20
Long-term study to assess the safety and efficacy of Nemolizumab in subjects with Atopic Dermatitis Ended

2024-514404-13-00 Atopic Dermatitis 5 2020-10-01
A phase III multi-center, randomized, open-label trial to evaluate efficacy and safety of ribociclib with endocrine therapy as adjuvant trea… Ended

2023-510357-42-00 hormone receptor (HR)-positive, HER2-negative, early br 5 2019-05-22
A Pharmacokinetics (PK) study to compare GME751 (proposed pembrolizumab biosimilar) and United States (US)-licensed and European Union (EU)-… Ended

2023-506881-30-00 Melanoma 3 2024-05-15
A study evaluating the effects of GLPG3667 given as oral treatment for up to 24 weeks in adults with dermatomyositis Ended

2022-501097-19-00 dermatomyositis 4 2023-08-09
Study of efficacy and safety of LNP023 in primary IgA nephropathy patients. Ended

2024-511067-29-00 IgA Nephropathy 5 2021-01-25